Ten out of 14 members of an FDA advisory panel that recommended a heart valve repair device from Abbott Laboratories had received payments from the company, but these conflicts of interest were not disclosed at the public meeting. This information was discovered by KFF Health News, who found the payments listed in the Open Payments database. While FDA regulations do not require disclosure of industry payments to panel members, it is the norm at medical conferences. Speakers at a recent conference where the device was discussed did disclose any industry ties. This raises concerns about transparency and potential conflicts of interest in the FDA approval process.
Source link
Most members on FDA advisory panel that recommended cardiac device had received payments from its maker
